1. Re-infection following sustained virological response with a different hepatitis C virus genotype: implications for infection control policy
- Author
-
Veronica M. Francis, Frank E. Murray, Margaret Duffy, John O'Regan, Sharon Dwyer, Peter J. Conlon, Jeff Connell, Michelle M. O’Shaughnessy, and Lelia Thornton
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Hepatitis C virus ,medicine.disease_cause ,Clinical Reports ,Pegylated interferon ,Genotype ,Epidemiology ,medicine ,Infection control ,Dialysis ,re-infection ,Transplantation ,business.industry ,virus diseases ,Hepatitis C ,medicine.disease ,infection control ,digestive system diseases ,Nephrology ,Immunology ,Clinical Cases ,dialysis ,Hemodialysis ,hepatitis C ,sustained virological response ,business ,medicine.drug - Abstract
We report the case of a 45-year-old haemodialysis patient who achieved a sustained virological response (SVR) following pegylated interferon therapy for hepatitis C virus (HCV) genotype 2 infection. He was subsequently cohorted with other HCV-infected dialysis patients and became re-infected with HCV genotype 3a. Epidemiological and molecular investigations identified a highly viraemic HCV genotype 3a-infected dialysis patient as the likely source of this infection. This critical incident informed a revision to local and national infection control policy regarding the dialysis management of patients who achieve an SVR following anti-viral treatment.
- Published
- 2012